In the first three years of the trial, just 1.7% of participants were Black. The lead researcher had to admit, she needed help. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

This clinical trial wanted to end breast cancer disparities. But first it needed to enroll Black women By Angus Chen CONSTANZA HEVIA FOR STAT Cancer surgeon Laura Esserman (above) was determined from the start that her breast cancer screening trial would have broad representation from people of color. Instead, she has learned a lot about how big the gap is between good intentions and good results. Without a host of strategies tailored to gain the participation of specific communities, a clinical trial may need what Consuelo Wilkins, a professor of medicine and a health equity expert at Vanderbilt University, calls a rescue. Read More Sponsor content by STAT+ This 4th of July, access indispensable insights for 25% off At STAT, our mission is to deliver trusted journalism that examines controversies and punctures hype. This Independence Day, get 25% off everything STAT has to offer — including STAT+, STAT Reports, and the 2022 STAT Summit. Learn more at statnews.com/fourth. More great reads from STAT this week Cue Health rode Covid-19 to an NBA deal and a $3 billion valuation. Now it faces layoffs and a rocky future By Katie Palmer In a doctor’s suspicion after a miscarriage, a glimpse of expanding medical mistrust By Eric Boodman After abortion ruling, biotechs developing contraceptives say their work is more important — and fraught — than ever By Jonathan Wosen Health tech companies are scrambling to close data privacy gaps after abortion ruling By Katie Palmer and Casey Ross A rich Republican businessman is an unlikely champion for lower hospital prices — but he’s winning the fight By Rachel Cohrs Medicare wants to stop publishing some hospital safety data next year By Tara Bannow Listen: Vertus Hardiman and the medical tragedies that must not be forgotten By Nicholas St. Fleur What we know — and what we may never know — about why the FDA banned Juul By Nicholas Florko Opinion: The next epidemic may be here. The U.S. isn’t ready for it By David C. Harvey CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade By Megan Molteni Saturday, July 2, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser